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ScienceDirectImmunotherapies revolutionised the treatment of several
disorders but show specific side-effect profiles which
frequently involve psychological symptoms. Long term
interferon-alpha (IFN-alpha) therapy can cause wide-ranging
psychiatric side-effects from fatigue, insomnia, anxiety to full-
blown depression. This treatment-emergent depression shares
several symptoms with major depressive disorder (MDD) with a
predominance of somatic/neurovegetative symptoms, and can
be treated with antidepressants. However, this experience
directed research to inflammatory mechanisms in MDD. MDD
has been confirmed as a heterogeneous disorder with a
subgroup of patients suffering from low-grade chronic
inflammation and frequently resistant to traditional
antidepressant treatment. Thus future research should develop
strategies to identify those MDD patients who could benefit
from drugs acting through inflammatory pathways.
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Introduction
Immunotherapy is a special biological therapy targeted at
activating the innate immune system to fight infections orwww.sciencedirect.com cancer, or downregulate immune response in case of auto-
immune disorders or allergies. Immunotherapies that boost
immune response against tumour cells or viruses are fre-
quently associated with early neurovegetative symptoms
characterised by fatigue, psychomotor slowing, anorexia
and pain [1]. These symptoms show a significant overlap
with the manifestations of the so-called sickness behav-
iour, caused by the activation of proinflammatory cytokines
during infections and including symptoms of fatigue, an-
hedonia, low mood, social isolation and irritability [2].
Sickness behaviour is considered an adaptive response
to promote healing by reducing energy expenditure to-
wards not necessary activities and decreasing exploratory
behaviour, thus it resembles a behavioural pattern very
similar to anxiety and depressive symptoms. Depressive
components including anhedonia, heightened pain sensi-
tivity, and social avoidance are meant to conserve energy to
fight the infection, while the anxious components were
developed to avoid further conflicts which might have
negative outcome on the healing process [3,4]. Thus,
an evolutionary advantageous behavioural effect of im-
mune response, which enhances survival, is also a disturb-
ing side effect of life saving immunotherapies leading to
significant suffering, burden and loss of quality of life, and
thus limiting the completion of the treatment course.
Because of the sharp increase in the number of different
immunotherapies and their indications in the present
review we focus on the psychological side effects of the
most frequently investigated interferon-alpha (IFN-alpha)
treatment and shortly summarise the side effects of the
newly developed immune checkpoint blocking agents.
Proinflammatory cytokines in the therapy:
IFN-alpha
Interferons are a superfamily of proinflammatory cyto-
kines that play a role in host defence mechanisms. IFN-
alpha is a natural cytokine which has a synthetic version:
IFN alpha-2b. IFN-alpha and IFN alpha-2b bind to
interferon type-1 receptors, activating a signal transduc-
tion pathway leading to the expression of multiple genes
responsible for inhibition of tumour cell growth and
proliferation [5]. IFN-alpha is widely used in antiviral,
for example, hepatitis C [6], and antitumor therapies such
as malignant melanoma or hairy cell leukaemia [7,8].
Psychological symptoms during IFN-alpha therapy
Besides early neurovegetative symptoms which manifest
in the majority of patients during the first weeks of IFN-
alpha treatment as fatigue, pain and anorexia, long-termCurrent Opinion in Pharmacology 2016, 29:97–103
98 ImmunomodulationIFN-alpha treatment often causes a wide variety of psy-
chiatric side-effects, such as depression, fatigue, insom-
nia, anxiety, and cognitive disturbances [1]. 10–40% of
patients additionally develop a full depressive disorder
syndrome that can include suicidal ideation, aboulia, lack
of motivation, social withdrawal, guilt, anhedonia, irrita-
bility, anxiety, and crying [9]. Mania, delirium, and psy-
chosis are further but less common side effects of IFN-
alpha treatment. Approximately 30–70% of hepatitis C
virus-infected patients treated with IFN-alpha experi-
ence different degrees of depression. Most of them suffer
from mild or moderate depressive symptoms, while se-
vere major depression occurs in about 15% [10].
In addition to these similarities, the symptom profile
(Table 1) of treatment-emergent depression and natu-
rally occurring major depressive episode show some
distinctions [11]. Namely, during long-term IFN-alpha
treatment patients reported more severe weight loss and
decreased activity, while feeling of guilt was less promi-
nent compared to medically healthy depressed subjects
[12]. This observation was supported by a recent finding
which suggested that risk genetic variant in the IL-6 gene
more specifically increased depressive symptoms mea-
sured by the Zung Self-rating Depression Scale com-
pared to the Brief Symptom Inventory, suggesting that
inflammatory risk mechanisms are more responsible for
somatic/neurovegetative symptoms than cognitive-emo-
tional signs of depression [13]. Furthermore, newly
developed immune checkpoint inhibitors, such as anti-
cytotoxic T-lymphocyte anti-gen 4 (CTLA-4) antibodies
or humanised immunoglobulins against programmed
death 1/ligand 1 (PD-1/PD-L1) which also enhance
tumour-specific immune activity are associated with aTable 1
Symptom profile of sickness behaviour, major depressive disorder, 
immune checkpoint inhibitors
Symptom domain Symptom Sickness 
behaviour 
MDD
Mood depressed mood x xxx
 anhedonia x xxx
 guilt  x 
 suicidal thoughts  x 
Anxiety tension/irritability x x 
 fear x x 
Cognitive memory/concentration  x 
 decision making  x 
Somatic/neurovegetative appetite x   x   
 sleep xx   x   
 psychomotor 
retardation  
xx x 
 fatigue xx x 
 pain x x 
MDD: major depressive disorder, IFN -alpha: interferon alpha treatmen
checkpoint inhibitor treatment, x: symptom is present, number of x: do
MDD: major depressive disorder, IFN-alpha: interferon alpha treatment, ICI:
of x: dominance of symptoms.
Current Opinion in Pharmacology 2016, 29:97–103 new category of side effects called ‘immune-related
adverse events’ (irAE), in which the most frequent
symptom is fatigue [14]. However, treatment-induced
depression has not been detected in relation to these new
drugs [15].
Distressing and frequently untreated depression is a
major contributor to dosage reductions or treatment dis-
continuations during IFN-alpha therapy and consequent-
ly increases the risk of ineffective treatment outcome or
relapse [16,17]. Thus, it is of great clinical importance to
investigate the mechanism underlying IFN-alpha-in-
duced depression and possible preventive strategies.
Potential mechanisms of IFN-alpha-treatment-induced
depressive symptoms
IFN-alpha is a strong activator of the proinflammatory
cytokine system by increasing the peripheral concentra-
tion of interlekin-6 (IL-6), interleukin 1-beta (IL-1b) and
tumour necrosis factor-alpha (TNF-a) [18]. Recent neu-
roimaging findings showed that acute administration of
IFN-alpha elicited an instant and profound decrease in
brain functional network connectivity which resulted in
changes in mood and cognitive symptoms [19]. In
addition, long-term IFN-alpha treatment was associated
with increased glutamate level in the basal ganglia and
dorsal anterior cingulate cortex (dACC) [20] which might
explain the previously reported increased ACC activation
and impaired error processing in IFN-alpha treated
patients [21].
However, remain the question how the cytokine imbal-
ance in peripheral plasma samples, induced by IFN-alpha
treatment, could spread into the brain which is protectedIFN-alpha induced depression, and psychological side effects of
 IFN-α ICI 
 xxx  
 (x)  
(x)  
(x)  
xx  
xx  
x  
x  
 xxx    
 x    
xxx  
xxx xxx 
xxx  
t, ICI: immune 
minance of symptoms 
 immune checkpoint inhibitor treatment, x: symptom is present, number
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Depression and immune therapies Kovacs et al. 99by the blood–brain barrier (BBB) (Figure 1). There are
three main proposed pathways how inflammatory activa-
tion can reach the brain to exert its effect on mood. First,
cytokine molecules can cross the BBB in some areas using
specific transport proteins, and also by non-specific trans-
port in the circumventricular organs, including the area
postrema, or the subfornical organ. Second, afferent nerve
fibres (e.g. vagus) can also carry the inflammatory signals
to the brain when inflammatory cytokines bind to cyto-
kine receptors and transmit these signals into the central
nervous system [22]. Third, there is a cellular pathway
where whole activated immune cells can reach the
brain with the help of CC-chemokine ligand 2 (CCL2),
and CXC-chemokine ligand 1 (CXCL1). Peripherial
cytokines, such as TNF, can induce the transport byFigure 1
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proinflammatory signal in the brain works in the opposite direction compare
activating the kynurenine pathway. The neurotoxic kynurenine metabolites, 
plasticity, and also oxidative radicals damage neural pathways leading to d
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www.sciencedirect.com activating the microglial production of these chemokines,
and also by inflammatory stimulated astrocytes [23]. Post
mortem studies of suicide victims who also suffered from
depression revealed increased CCL2 expression and mac-
rophage numbers in the perivascular space, suggesting
increased transport of activated immune cells into the
brain in depressive state [24].
Decreased neural plasticity
Besides activated cells crossing the BBB, microglial cells
which have the original purpose of fighting infections
inside the CNS also produce cytokines such as TNF-a
and IL-1b. Overactivation of microglial cells is commonly
reported in association with depressive states. Prolonged
elevation of cytokine levels inside the brain can inducePlasticity
ROS,RNS
Neurotoxicity
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-induced depression. Activation of the immune system during specific
atment, recent negative life events or chronic pain induces depression-
 cross the blood–brain barrier (BBB), and reach the central nervous
e microglial cells, producing attracting chemokines, and facilitating the
lial cells can also be activated by psychosocial stress. The
d to the effect of antidepressants, suppressing 5-HT activity, and
and the lower BDNF and NF-KB levels promote reduced neural
epression-specific morphological changes. 5-HT: serotonin, AD:
 anti-gen 4, Anti PD-1: antibody against programmed death 1/ligand 1,
XCL1: CXC-chemokine ligand 1, IDO: indolamine-2,3-dioxygenase, IL-
lear factor kB, ROS: radical oxygen species, RNS: radical nitrogen
umour necrosis factor.
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100 Immunomodulationneural apoptotic pathways through their effect on nuclear
factor kB (NF-kB) and brain-derived neurotrophic factor
(BDNF), resulting in impaired neuronal plasticity, and
promoting depression-specific morphological alterations
[25].
Decreased neurotransmitter availability
Proinflammatory cytokines can also influence neural plas-
ticity through the activation of indolamine-2,3-dioxygen-
ase (IDO) which is the rate limiting enzyme of kynurenine
production. IDO is an enzyme which converts tryptophan
into kynurenine, thus competing for tryptophan with the
serotonine pathway [26]. Lower tryptophan availability
itself can cause depressive symptoms under experimental
conditions, but lower serotonergic function is also com-
monly found in depressed individuals.
Increased neurotoxicity
Besides the lower amount of tryptophan left for serotonin
synthesis, activation of the kynurenine pathway also pro-
duces potentially neurotoxic metabolites. For example,
quinolinic acid which is elevated in post-mortem de-
pressed suicide victims’ brain acts as an N-methyl-D-
aspartate (NMDA) receptor agonist, and also contributes
to disturbances in glutamate reuptake and release from
astrocytes, leading to excitotoxic neuronal damage [27].
Interesting to note that IDO hyperactivity correlated with
long-term depression-specific symptoms (depressed mood,
anxiety) but not with early neurovegetative symptoms
(pain, fatigue, anorexia) during cytokine therapy [28].
Increased oxidative stress
Inflammatory activation is also accompanied by increased
production of radical oxygen (ROS) and radical nitrogen
species (RNS). The activity of tetrahydrobiopterin (BH4)
which is necessary for monoamine synthesis, is reduced by
oxidative radicals, suggesting lower synthesizing capacity
in the presence of inflammation. These oxidative sub-
stances are damaging for DNA, fatty acids, and proteins
alike especially in neural cells which are the most vulner-
able to oxidative stress. Alterations in neural cell mem-
brane structure, serotonin binding capability, and
intracellular signalling mechanisms due to oxidative stress
all contribute to impaired serotonergic activity and tissue
damage. Furthermore, superoxide anion radicals (SAR)
behave as a co-substrate of IDO causing superinduction of
the kynurenine pathway in the presence of excessive
oxidative stress, thus oxidative radicals and kynurenine
seems to form a self-enhancing loop which reduces the
survivability of neuronal cells greatly [29].
Difference between the mode of action of IFN-alpha and
immune checkpoint inhibitors
Although both IFN-alpha and immune checkpoint inhi-
bitors increase tumour specific immune response their
psychological side-effect profiles are strikingly different.
It has been recently demonstrated that CTLA-4 antibodiesCurrent Opinion in Pharmacology 2016, 29:97–103 (e.g. ipilimumab) decrease the number of regulatory
Treg cells through non-classical monocytes [30]. Nonclassi-
cal or patrolling monocytes are responsible for clearing up
the consequences of inflammation at the vascular endo-
thelium and maintaining the integrity of the BBB thus they
might decrease expansion of the inflammation into the
central nervous system [31]. PD-1/PD-L1 antibodies (e.g.
nivolumab and pembrolizumab, both approved in 2014)
increase effector T cell activity within tissues or tumours
where cells express PD-1/PD-L1 which tends to be low in
the brain [14,32].
Risk factors of psychological side effects during IFN-
alpha treatment
It has been observed that behavioural effect of inflamma-
tion shows differences between patients. Thus knowl-
edge of risk factors for developing depression would be
useful in clinical practice to prevent such adverse effects
[33]. One major risk factor is presence of psychiatric
disorders, especially depression in the medical history
possibly because of shared biological mechanisms. For
example, it has been demonstrated that increased preva-
lence of depression in females might be explained by the
greater sensitivity of females to inflammatory signals both
at the biochemical and behavioural level [34].
Potential genetic risk factors
Genetic variants that have been implicated in depression
like the serotonin transporter gene functional promoter
polymorphism (5-HTTLPR) [35,36], or other serotonin
(e.g. HTR1A) or inflammatory (e.g. IL-6, COX-2, TNF-
alpha) pathway related genetic variants increase the risk
of developing psychological side effects during IFN-
alpha treatment [33,37]. Furthermore, several genetic
variants throughout the interferon a/b signalling pathway
[38], and genetic variants in the IL-6, IL-1b or nitric
oxide synthase-1 (NOS1) genes increase depressive and
anxiety symptomatology, especially in the presence of
psychosocial stressors in general populations [13,39,40].
Psychosocial stress
It has been consistently reported that psychosocial stress is
a potent inductor of inflammatory response both in ani-
mals and humans [41,42]. Sterile stressors, like negative
life events, are able to activate inflammosomes, a complex
cytosolic protein cascade with the original role in pathogen
host-defence reaction. The main products of inflammo-
somes are inflammatory cytokines such as IL-1B, Il-6,
TNF-a, and CRP [22,43]. These cytokines are considered
to be one of the most stable biomarkers for depression. In
addition, stress exerts not only an acute but a long-term
effect on inflammation. For example, childhood trauma
permanently upregulates proinflammatory cytokines,
probably through epigenetic changes [25,44]. In addition,
patients with sensitized stress response pathways are more
vulnerable to interferon IFN-alpha-induced depression.
For example, patients who responded to a first dose ofwww.sciencedirect.com
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tary-adrenal axis (HPA) were significantly more likely to
develop major depression during treatment than patients
with modest stress system responses to the initial injection
[45].
Social support as a protective factor
It is important to note that social support is able to
decrease the risk of depression both in a general popula-
tion and in patients treated with immunotherapies [46].
Social support has been associated with decreased HPA
activity and glucocorticoid concentration [47,48], with
diminished dACC activity after social stressor [48], and
with decreased proinflammatory cytokine production dur-
ing stress [49]. Indeed, melanoma patients with increased
social support were less likely to develop depressive
symptoms during low-dose IFN-alpha treatment [50].
Prevention of IFN-alpha induced psychological
symptoms
Screening and evaluation of risk factors such as psychiat-
ric history, genetic polymorphisms, premorbid elevations
in inflammatory cytokines, or social support may help to
initiate personalized prevention therapy in those who are
likely to develop psychiatric side effects during IFN-
alpha treatment [9]. Multiple studies found that prophy-
lactic and concurrent treatment with selective serotonin
reuptake inhibitors (SSRIs) successfully reduced the
incidence and severity of major depression in patients
with chronic hepatitis C infection or malignant melanoma
treated with IFN-alpha-2b [51]. In addition, preliminary
studies suggest that a diet rich in omega-3 polyunsaturat-
ed fatty acids which promote anti-inflammatory processes
in the body and may also process mood-stabilising effects
thus may prevent somatic depressive symptoms in cyto-
kine-treated patients [52]. However, it is interesting to
note that (non IFN-alpha induced) major depressive
patients with an elevated inflammatory biomarker profile
typically respond poor to standard antidepressant or anti-
psychotic treatment [53].
Conclusions of experience with immune-influencing
agents for treating major depressive disorder
Introduction of immunotherapies have not only advanced
the treatment of tumours, virus infections, autoimmune
diseases and allergies but also shed light on the patho-
mechanism of depression. Now it is increasingly accepted
that major depressive disorder is a heterogeneous condi-
tion concerning both its manifestation and its underpin-
nings, and covers several distinct ethiopathologic routes,
one of them being chronic low grade-inflammation, that
converge to the emergence of similar symptoms [4].
Indeed, SSRI-type antidepressants are able to counteract
the effect of inflammatory mechanisms of depression to a
certain degree. For example there is experimental evi-
dence that release of TNF-a, NO, and IL-6 from micro-
glial cells in response to IFN-g administration can bewww.sciencedirect.com impaired by certain SSRI-type antidepressants [54], and
they are able to shape the immune response in the
peripheral immune cells as well [55]. However, as men-
tioned above, an elevated inflammatory biomarker profile
predicts poor treatment response to first choice (typically
SSRI) antidepressants. For example, patients with higher
C-reactive protein levels improved better on nortriptyline
compared to escitalopram [56]. Thus, patients who are
refractory to standard antidepressant pharmacotherapies
should be screened for inflammatory biomarkers to adjust
their treatment. Supporting the alternative therapeutic
approach there are studies reporting cyclooxygenase and
nitric oxide synthase inhibitors exerting antidepressant-
like activity [29]. In addition, minocycline, an antibiotic
substance with capability to reduce microglial activation
was able to restore hippocampal neurogenesis and thus a
potential candidate in depression treatment [57]. More-
over, TNF-a antagonist infliximab showed a higher re-
duction of depression scores compared to placebo in
patients with treatment-resistant depression and higher
CRP levels [58]. Thus drugs targeting the inflammatory
biological pathways might be a way forward in a subset of
depressed patients who do not improve on standard
antidepressant treatment.
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